Endometriosis & Fibroids Screening

Florya assesses pelvic pain patterns, menstrual symptoms, and inflammatory markers using criteria aligned with ASRM (American Society for Reproductive Medicine) guidelines. While laparoscopy is the gold standard for diagnosis, our screening identifies risk indicators that warrant further investigation.

Florya screens for fibroid risk factors by analyzing symptoms like heavy menstrual bleeding, pelvic pressure, and pain patterns. Our assessment can identify patterns that suggest fibroids and recommend appropriate imaging (pelvic/transvaginal ultrasound).

Screening identifies risk indicators and symptom patterns suggestive of endometriosis. Formal diagnosis typically requires imaging or surgical confirmation. Florya provides the structured evidence your doctor needs to justify further investigation.

While laparoscopy remains the gold standard for definitive diagnosis, non-invasive approaches are improving. Symptom-based screening tools, transvaginal ultrasound, MRI, and biomarkers like CA-125 can identify endometriosis risk indicators without surgery. Florya combines symptom pattern analysis with biomarker correlation to provide a non-invasive risk assessment.

CA-125 is the most commonly studied blood marker for endometriosis, though it is not definitive on its own. Elevated CRP and ESR (inflammatory markers) may also indicate the chronic inflammation associated with endometriosis. Florya correlates these markers with your symptom profile for a more comprehensive assessment.

Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus, causing inflammation and pain. Uterine fibroids are non-cancerous growths within the uterine wall that can cause heavy bleeding and pelvic pressure. Both conditions can coexist and share symptoms like pelvic pain, which is why Florya screens for both simultaneously.